Initiates Coverage on Can-Fite BioPharma (NYSE:CANF) began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report released on Sunday morning. The brokerage issued a hold rating on the stock. A number of other brokerages have also issued reports on CANF. HC Wainwright decreased their price target on Can-Fite BioPharma from $34.00 to $18.00 and set […]

Leave a Reply

Your email address will not be published.

Previous post AMREP (NYSE:AXR) Rating Increased to Buy at
Next post Orioles promote Matt Blood to oversee draft operations after losing Brad Ciolek to Nationals